CN1663610A - Lysozyme preparation - Google Patents
Lysozyme preparation Download PDFInfo
- Publication number
- CN1663610A CN1663610A CN 200410015491 CN200410015491A CN1663610A CN 1663610 A CN1663610 A CN 1663610A CN 200410015491 CN200410015491 CN 200410015491 CN 200410015491 A CN200410015491 A CN 200410015491A CN 1663610 A CN1663610 A CN 1663610A
- Authority
- CN
- China
- Prior art keywords
- preparation
- lysozyme
- tablet
- prevent
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to new oversize preparation method for lysozyme, which is that adding dose for new preparation based on already preparation, such as oral preparation for tablet, capsule, granule, buccal tablets, effervescent tablet, vagina effervescent tablet, etc, every preparation unit contains lysozyme 20~10000mg; injection types such as liquid drugs injection, transfusion, powder injection and freeze dried injection, every preparation unit contains lysozyme 1mg~100g per needle. The preparation can be used effectively to prevent and treat for all kinds infection and inflammation bacteria brought by bacterial and virus from clinic, controlling anaphylactic rhinitis, chronic rhinitis, health caring and protecting corrosion for buccal cavity and dens, pharyngolaryngitis brought by smoking, and prevent all kinds hemorrhage, also can used to defence infection immunoreaction with non-specific, blood coagulation action, repairing gap junction tissue, participating biological anabolism and antibiosis of mucopolysaccharide, and is used for pain relieving of cancer, prevent leukocytopenia brought by chemotherapy or radiotherapy for cancer patient.
Description
● invention field
The present invention relates to the new big specification preparation way of lysozyme.This mode is that novel formulation increases specification on the basis of original preparation, at 20-10000mg, the lysozyme content of each preparation unit such as the liquid drugs injection of injection type, transfusion, powder pin and lyophilized injectable powder props up at 1mg-100g/ as the lysozyme content of each preparation unit such as tablet, capsule, granule, buccal tablet, effervescent tablet and vagina effervescence of oral formulations.Those preparations are applicable to various clinically antibacterials and the viral infection that causes, the treatment and the prevention of inflammation, and prevent and treat the health care corrosion protection of allergic rhinitis, chronic rhinitis and Buccodental and the pharyngolaryngitis that smoking causes, with prevent various forms of hemorrhage, also can be used to comprise the reparation of the reaction of nonspecific defence infection immunity, hemagglutinative function, gap conjunctive tissue, the biosynthetic metabolism that participates in mucopolysaccharide and antibacterial action etc. and be used for the pain relieving of cancer and prevent and treat the leukopenia that carninomatosis patient chemotherapy or radiotherapy etc. cause.
● background technology
Lysozyme (Lysozyme) is a human body endogenous organized enzyme, and it is widely distributed in the multiple organ-tissues such as people body-centered, liver, spleen, lung, kidney.Wherein the highest with kidney and lung content, hemocyte such as mononuclear cell, macrophage also contain this enzyme, and blood and various secretions etc. are lysozyme all.Lysozyme continues synthetic and secretion by granulocyte and mononuclear cell, because it has stronger bactericidal action and viricidal activity to gram positive bacteria, is a kind of important humoral immunization factor in the human body nonspecific immunity therefore.
Lysozyme is a glycoside hydrolase, and its antibacterial action is by acting on β-1,4 key between N-acetylglucosamine and the-acetylmuramic acid, can making the mucopolysaccharide composition hydrolysis in some bacteria cell wall, thereby have the bacteriolyze ability.The lysozyme antibiotic effect is by β-1,4 glycosidic bond between the N-acetylglucosamine in the cell wall that destroys antibacterial, makes the insoluble mucopolysaccharide of cell wall resolve into the solubility glucosides, causes cell wall rupture, and cellular content is overflowed and made bacterolysis.Lysozyme can also combine with the various acidic materials that bring out inflammation, makes its inactivation.Lysozyme is used for various antibacterials and the viral infection that causes, the treatment and the prevention of inflammation clinically, and prevent and treat the health care corrosion protection of allergic rhinitis, chronic rhinitis and Buccodental and the pharyngolaryngitis that smoking causes, with prevent various forms of hemorrhagely, also can be used to comprise the reparation of the reaction of nonspecific defence infection immunity, hemagglutinative function, gap conjunctive tissue, the biosynthetic metabolism that participates in mucopolysaccharide and antibacterial action etc.
The lysozyme antivirus action is by combining with electronegative virus protein, form double salt with RNA, DNA, apoprotein, making virally inactivated.The up-to-date result of study of delivering shows: lysozyme anti-HIV-1 type virus mechanism is the same with the RNA enzyme.
Lysozyme also is used to the pain relieving of cancer and prevents and treats the leukopenia that carninomatosis patient chemotherapy or radiotherapy etc. cause.It also has the anti-fibrinolitic effect, is used to prevent capillary hemorrhage, strengthens blood vessel wall, occasions such as epistaxis, bloody sputum, spitting of blood, hematuria and postoperative hemorrhage.Lysozyme is an endogenous active substance, be one of the extraneous self-defense response mechanism of invading of human body self opposing, nonspecific immunity factor, its enhancing immunity effect is by strengthening macrophage and leukocytic phagocytic function, and improve the leukopenia that cytostatics causes, strengthen the immunity of cell.
Lysozyme is a clinical use old medicine for many years, and is the OTC medicine, and the lysozyme raw material that uses clinically all is to extract from Ovum Gallus domesticus album at present, and its safety has obtained the proof of clinical use for many years.But owing to adopt traditional extraction technique, wherein impurity can't be removed totally, lysozyme formulation is originally influenced by this, because anaphylaxiss such as the erythra that impurity causes, drug fever, slight bronchospasm can't prepare big specification preparation, ejection preparation is owing to the side effect reason causes clinical practice also seldom simultaneously.Now, adopt the height ratio lysozyme alive of new purification technique and biotechnology preparation to obtain success, fundamentally solved the problem of lysozyme activity and purity, made that the lysozyme formulation for preparing big specification becomes possibility because the anaphylaxis that impurity causes reduces greatly.
The present invention adopts the lysozyme formulation that height ratio is lived, highly purified lysozyme prepares big specification.These preparations comprise oral formulations and ejection preparation.
The present invention relates to new lysozyme large-size oral preparation way.These preparations can be gelatine capsule, plant capsule, granule, dispersible tablet, buccal tablet, effervescent tablet, vagina effervescence, coated tablet, medicine bag, coated tablet, lozenge, suppository, powder, oral liquid, the slow release formulation of drinking bottle or solution, microgranule or above-mentioned various dosage forms, enteric dosage form, disperse dosage form.The lysozyme content of each preparation unit is the lysozyme enteric coatel tablets of 200mg at 20-10000mg as specification.
When adopting drug administration by injection, these preparations are injection solution, dry powder or the lyophilized powder and the form of suspension that are packaged in phial, vial or bottle that are used for venoclysis at a slow speed or intramuscular injection, and the lysozyme content of each preparation unit props up at 1mg-100g/.
In the preparation process of these preparations, adopt pharmaceutically acceptable Technology, active substance and all kinds excipient or carrier such as filler, disintegrate (or broken) agent, binding agent, dyestuff, correctives or the like are mixed, then mixture is shaped, be prepared into preparation thus.
These preparations are applicable to various clinically antibacterials and the viral infection that causes, the treatment and the prevention of inflammation, with prevent various forms of hemorrhage, also can be used to comprise the reparation of the reaction of nonspecific defence infection immunity, hemagglutinative function, gap conjunctive tissue, the biosynthetic metabolism that participates in mucopolysaccharide and antibacterial action etc. and be used for the pain relieving of cancer and prevent and treat the leukopenia that carninomatosis patient chemotherapy or radiotherapy etc. cause.
The present invention relates to new heavy dose of lysozyme formulation mode, the problem that this preparation way has solved tradition, the low dosage lysozyme is lower than living, side effect is big, dosage is big, onset is slow, bioavailability is lower etc. is for clinical use provides new selection.
● embodiment
Example one: the preparation of height ratio lysozyme medicinal raw material alive
From the humanized lysozyme raw material that extracts in Ovum Gallus domesticus album, the Urina Hominis/tear or biological engineering is expressed, through refining purification, check albumen than living and surpass 1500U/mg, reach medicinal standard.
Example two: the preparation of big specification lysozyme powder injection
Adopt the injection lysozyme raw material after making with extra care, press the operation of powder pin process, the preparation specification is the injectable powder of 2mg lysozyme.
Example three: the preparation of big specification lysozyme buccal tablet
The lysozyme raw material that adopts height ratio to live is pressed the procedure operation of enteric coatel tablets production technology, the lysozyme enteric coatel tablets of preparation specification 200mg.
Claims (3)
1, the new big specification preparation way of lysozyme.This mode is that novel formulation increases consumption on the basis of original preparation.These preparations are applicable to various clinically antibacterials and the viral infection that causes, the treatment and the prevention of inflammation, and prevent and treat the health care corrosion protection of allergic rhinitis, chronic rhinitis and Buccodental and the pharyngolaryngitis that smoking causes, with prevent various forms of hemorrhage, also can be used to comprise the reparation of the reaction of nonspecific defence infection immunity, hemagglutinative function, gap conjunctive tissue, the biosynthetic metabolism that participates in mucopolysaccharide and antibacterial action etc. and be used for the pain relieving of cancer and prevent and treat the leukopenia that carninomatosis patient chemotherapy or radiotherapy etc. cause.
2, according to the oral formulations of claim 1, as the dispersible tablet of tablet, capsule, granule, oral liquid, buccal tablet, effervescent tablet and vagina effervescence etc. and these preparations, enteric coatel tablets, slow releasing tablet etc., these formulation characteristics are that the lysozyme content of its unit formulation is at 20-10000mg.
3, according to the ejection preparation of claim 1, as various forms such as the vial of liquid drugs injection, transfusion, powder pin and lyophilized injectable powder etc. and these preparations, cillin bottle, flexible packagings, these formulation characteristics are that the lysozyme content of its unit formulation is at 1mg-100g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410015491 CN1663610A (en) | 2004-03-01 | 2004-03-01 | Lysozyme preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410015491 CN1663610A (en) | 2004-03-01 | 2004-03-01 | Lysozyme preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1663610A true CN1663610A (en) | 2005-09-07 |
Family
ID=35035038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410015491 Pending CN1663610A (en) | 2004-03-01 | 2004-03-01 | Lysozyme preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1663610A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103272224A (en) * | 2013-06-26 | 2013-09-04 | 乔敏 | Lysozyme sugar lozenge and preparation method thereof |
| CN105749261A (en) * | 2016-05-11 | 2016-07-13 | 山东司邦得制药有限公司 | Composite hydrochloric acid lysozyme vagina tablet and preparation method thereof |
| CN105749260A (en) * | 2016-05-11 | 2016-07-13 | 山东司邦得制药有限公司 | Lysozyme hydrochloride vaginal tablets, and preparation method and application thereof |
| CN107569395A (en) * | 2017-09-04 | 2018-01-12 | 天津医科大学口腔医院 | It is a kind of to make the material of desensitizing dental for closing dentinal tubule |
| WO2021012789A1 (en) * | 2019-07-19 | 2021-01-28 | 广州新创忆药物临床研究有限公司 | Pharmaceutical composition containing lysozyme and use thereof |
-
2004
- 2004-03-01 CN CN 200410015491 patent/CN1663610A/en active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103272224A (en) * | 2013-06-26 | 2013-09-04 | 乔敏 | Lysozyme sugar lozenge and preparation method thereof |
| CN105749261A (en) * | 2016-05-11 | 2016-07-13 | 山东司邦得制药有限公司 | Composite hydrochloric acid lysozyme vagina tablet and preparation method thereof |
| CN105749260A (en) * | 2016-05-11 | 2016-07-13 | 山东司邦得制药有限公司 | Lysozyme hydrochloride vaginal tablets, and preparation method and application thereof |
| CN105749260B (en) * | 2016-05-11 | 2020-07-17 | 山东司邦得制药有限公司 | Lysozyme hydrochloride vaginal tablet and preparation method and application thereof |
| CN105749261B (en) * | 2016-05-11 | 2020-07-17 | 山东司邦得制药有限公司 | Compound lysozyme hydrochloride vaginal tablet and preparation method thereof |
| CN107569395A (en) * | 2017-09-04 | 2018-01-12 | 天津医科大学口腔医院 | It is a kind of to make the material of desensitizing dental for closing dentinal tubule |
| CN107569395B (en) * | 2017-09-04 | 2020-08-11 | 天津医科大学口腔医院 | Material for closing dentinal tubules to desensitize teeth |
| WO2021012789A1 (en) * | 2019-07-19 | 2021-01-28 | 广州新创忆药物临床研究有限公司 | Pharmaceutical composition containing lysozyme and use thereof |
| CN112533628A (en) * | 2019-07-19 | 2021-03-19 | 广州新创忆药物临床研究有限公司 | Pharmaceutical composition containing lysozyme and application thereof |
| JP2022541173A (en) * | 2019-07-19 | 2022-09-22 | 広州新創憶薬物臨床研究有限公司 | Pharmaceutical composition containing lysozyme and use thereof |
| JP7314391B2 (en) | 2019-07-19 | 2023-07-25 | 広州新創憶薬物臨床研究有限公司 | Pharmaceutical composition containing lysozyme and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9504648B2 (en) | Matrix carrier compositions, methods and uses | |
| US3224942A (en) | Anti-inflammatory, anti-edema and anti-thrombi drug | |
| KR101117861B1 (en) | A forsythoside injection and preparation thereof | |
| ES2542879T3 (en) | Pharmaceutical composition to prevent dysbiosis associated with enteral administration of antibiotics | |
| EP1107722B1 (en) | A method for the treatment of staphylococcal infection | |
| CN1919170A (en) | Colloid pectin bismuth dry suspensoid and its preparing process | |
| CN1663610A (en) | Lysozyme preparation | |
| US20030109490A1 (en) | Composite stimulating iNOS enzyme which induce immuno-reactant nitric oxide synthesis and process for preparing the same | |
| CN108670951A (en) | A kind of compound sustained-released injection of gentamicin sulphate-Lincomycin Hydrochloride for animals and preparation method thereof | |
| CN101423516A (en) | Preparation of pidotimod sodium and medicinal use thereof | |
| CN101400255A (en) | Composition for treating bacterial, virus, fungal disease, inflammation and ache | |
| US20070141044A1 (en) | Method for treating cancer patients undergoing chemotherapy | |
| JP2004010605A (en) | Antitumor agent given by using mixture of deacetylated and deoxygenated mushrooms, fermented ganoderma spawn, and other mixture, and health food product, and feed additive containing the agent | |
| CN113521262A (en) | Lysozyme preparation with anti-inflammatory effect | |
| CN108310371B (en) | Blood fat reducing pharmaceutical composition and application thereof | |
| CN101768156A (en) | Pidotimod arginine salt and preparation thereof | |
| CN110917209A (en) | Application of selenium-containing compound or selenium nano-grade in preparation of injection or microneedle of arthritis treatment drug | |
| CN101554374B (en) | Flavonoid compound with inhibit function for dipeptidyl peptidase IV | |
| WO2005017139A1 (en) | Thrombin from venom of agkistrodon acutus used as drugs for the treatment of haemorrhage | |
| CN1552443A (en) | Lysozyme injection preparation | |
| CN1522759A (en) | Interferon and synergist combined pharmaceutical | |
| CN1679914A (en) | Medicinal composition of induced glutathione and ebeselen | |
| CN101647824A (en) | Bionic enzymatic hydrolysate for scorpion and application thereof | |
| JP2005239737A (en) | Method for producing new pharmaceutical composition for ameliorating quality of life and use of the composition | |
| CN1292793C (en) | Application of kininogenase of human urine in preparing medication for treating pyemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |